Recombinant Proteins iso9001 ISO13485
搜索
 > 【CD40】重组蛋白信息

CD40信息

英文名称:Tumor necrosis factor receptor superfamily member 5
中文名称:肿瘤坏死因子受体超家族成员5
靶点别称:B Cell-Associated Molecule,CD40 Antigens,Bp50,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CD40L Receptor,CD40,CDW40,Tumor Necrosis Factor Receptor Superfamily Member 5,TNFRSF5,
上市药物数量:0
临床药物数量:17
最高研发阶段:临床二期

CD40产品列表

 
评论(3)
TN5-M52H8|Mouse CD40 / TNFRSF5 Protein, His Tag
  1. 156XXXXXXX8
  2. 0人赞
  3. 采购的蛋白用于开展动物免疫,制备高亲和力抗体的工作。蛋白纯度符合要求,且能够与anti-CD40的商业化抗体结合,后面可用于筛选工作。
  4. 2021-02-19
CD0-H5228|Human CD40 / TNFRSF5 Protein, His Tag (MALS verified)
  1. 156XXXXXXX8
  2. 0人赞
  3. 蛋白用于免疫,用于制备高亲和力抗体。经过检测蛋白纯度符合要求,能够满足动物免疫工作,现已用于免疫,待后续开展筛选
  4. 2021-02-19
CD0-H5253|Human CD40 / TNFRSF5 Protein, Fc Tag (MALS verified)
  1. 182XXXXXXX2
  2. 2人赞
  3. 购买Human CD40的目的是用来与CD40L测定Fortebio测亲和力的,蛋白QC的纯度验证很高,与官网一致,亲和力还没有测完。
  4. 2019-09-26
 

CD40 分子别名

CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50

CD40 分子背景

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40 参考文献

CD40临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CD40L-GVAX GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF 临床二期 University Of South Florida 骨髓增生异常综合征, 肺癌, 黑色素瘤 详情
FFP-102 5-D12; PG-102 临床二期 Pangenetics 银屑病关节炎, 克罗恩病 详情
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) 临床一期 贝勒医学院 慢性淋巴细胞白血病 详情
2141-V11 2141-V11 Darell Bigner 详情
BI-655064 BI-655064 临床二期 勃林格殷格翰 特发性血小板减少性紫癜, 类风湿关节炎, 狼疮肾炎 详情
CDX-1140 CDX-1140 临床二期 Celldex 滤泡中心淋巴瘤, 非小细胞肺癌, 慢性淋巴细胞白血病, 黑色素瘤, 非霍奇金淋巴瘤, 输卵管癌, 巨球蛋白血症, 结直肠癌, 腹膜癌, 套细胞淋巴瘤, 乳腺癌, 胆管上皮癌, 边缘带B细胞淋巴瘤, 膀胱癌, 弥漫性大B-细胞淋巴瘤, 胰腺癌, 胃癌, 食道癌, 肾细胞癌, B-细胞淋巴瘤, 头颈癌, 卵巢癌, 肝癌 详情
NJA-730 NJA-730; NJA-730a; NJA-730b 临床一期 Napajen Pharma 移植物抗宿主病, 神经系统自身免疫疾病 详情
Mitazalimab ADC-1013; JNJ-7107; JNJ-64457107 临床一期 Alligator Bioscience 实体瘤, 肿瘤 详情
FFP-104 FFP-104 临床二期 Ff Pharma 胆汁性肝硬化, 克罗恩病 详情
Ravagalimab ABBV-323; PR-1629977 临床二期 艾伯维 溃疡性结肠炎 详情
SHR-1704 SHR-1704 临床一期 江苏恒瑞医药股份有限公司 血液疾病 详情
MEDI-5083 MEDI-5083 临床一期 阿斯利康, Medimmune 肿瘤 详情
APX-005M APX-005; APX-005M; EPI-0050 临床二期 Epitomics 头颈癌, 肾细胞癌, 食道癌, 胃癌, 胰腺癌, 移行细胞癌, 肉瘤, 脑癌, 微卫星不稳定, 胶质瘤, 肺癌, 黑色素瘤, 非小细胞肺癌 详情
Bleselumab 4D-11; ASKP-1240 临床二期 协和发酵工业 器官移植排斥, 局灶性节段性肾小球硬化症, 银屑病 详情
Anti-CD40 ChiLob7/4 (BioNTech) 临床二期 Biontech Se 头颈癌, 胰腺癌 详情
Iscalimab CFZ-533; NVP-CFZ533; OM11-62-MF 临床二期 诺华制药 重症肌无力, 肾脏移植排斥, 1型糖尿病, 肝脏移植排斥, 类风湿关节炎, Sjtoegren综合征, 狼疮肾炎, 系统性红斑狼疮, 格雷夫斯病, Sjogren-Larsson综合征, 化脓性汗腺炎 详情
SEA-CD40 SEA-CD40 临床一期 Seattle Genetics B-细胞淋巴瘤, 头颈癌, 头颈部鳞状细胞癌, 霍奇金病, 弥漫性大B-细胞淋巴瘤, 鳞状细胞肿瘤, 胰腺癌, 滤泡中心淋巴瘤, 淋巴瘤, 非霍奇金淋巴瘤, 鳞状细胞癌, 黑色素瘤, 非小细胞肺癌, 转移癌 详情
Selicrelumab RG-7876; RO-7009789 临床一期 罗氏 实体瘤, 胰腺癌, 肿瘤, 非霍奇金淋巴瘤 详情
YH-003 YH-003; YH003 临床一期 祐和医药科技(北京)有限公司 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定